Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
L. Peng, Y. Hu, M. Mankowski, P. Ren, R. Chen, J. Wei, M. Zhao, T. Li, T. Tripler, L. Ye, R. Chow, Z. Fang, C. Wu, M. Dong, M. Cook, , S. Chen
The paper develops and characterizes monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its variants, including B.1.617.2 Delta.
bioRxiv · Dec 21, 2021Immunology